Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
42 participants
INTERVENTIONAL
2023-02-01
2024-06-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Repeated Injectable PRF Following SRP in Patients With Periodontitis
NCT07029035
The Effects Of I-PRF On Gingivectomy and Gingivoplasty
NCT05871190
The Effectiveness of Root Planing and Injectable Platelet-Rich Fibrin in Smoking Patients With Periodontitis
NCT07049549
Applied The Platelet Rich Fibrin in Chronic Periodontitis
NCT02594605
Effects of i-PRF on Non-surgical Periodontal Treatment
NCT05753631
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This single-center, randomized, parallel-group, open-label clinical trial is designed to evaluate whether the adjunctive use of i-PRF after EDTA root conditioning provides additional benefits compared with EDTA conditioning alone. Adults with periodontitis will be enrolled at a university periodontal clinic and randomized to one of two groups:
Control group: OFD with 24% EDTA gel conditioning (3 minutes)
Test group: OFD with 24% EDTA gel conditioning (3 minutes) followed by application of i-PRF retained on defect surfaces for 5 minutes
A mixed defect model (sites with both intrabony and horizontal components) will be included to reflect real-world clinical presentations.
All participants will receive standardized Phase I therapy before surgery. On the day of surgery, an antiseptic rinse will be performed, local anesthesia will be administered, full-thickness flaps will be elevated, and meticulous debridement/root planing will be completed. In the test arm, i-PRF will be prepared from venous blood collected into plain glass tubes and centrifuged at \~700 rpm (60 g) for 3 minutes; the platelet-rich upper layer (\~1-1.5 mL per tube) will be aspirated and applied to the defect for 5 minutes before primary closure with 4-0 monofilament sutures. Postoperative care will include analgesic and/or anti-inflammatory medication as needed and an antiseptic mouthwash; systemic antibiotics will not be routinely prescribed. Sutures will be removed at approximately 1 week. A planned follow-up schedule will include weekly visits during the first month and monthly visits thereafter through month 6.
The primary outcome will be the change in probing pocket depth (PPD) at surgical sites at 6 months. Key secondary outcomes will include clinical attachment level (CAL), plaque and gingival indices, bleeding on probing, gingival recession depth and width, patient-reported pain and sensitivity (VAS), and postoperative clinical healing parameters such as edema, erythema, and necrosis, assessed at prespecified time points. Randomization will be computer-generated; surgeries and measurements will be performed by an experienced periodontist using calibrated probes.
The study has been approved by an institutional ethics committee and will be conducted in accordance with the Declaration of Helsinki and good clinical practice principles. The trial does not involve any U.S. FDA-regulated drug or device. An independent data monitoring committee will not be convened given the low-risk, single-center nature of the interventions; adverse events will be actively assessed at follow-up visits, and participants may withdraw at any time without penalty.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control - OFD + EDTA
Participants received open flap debridement (OFD) with 24% EDTA root surface conditioning only. No injectable platelet-rich fibrin (i-PRF) was applied.
Open Flap Debridement (OFD)
Standard periodontal surgical procedure involving full-thickness flap elevation, scaling, and root planing to eliminate inflamed tissue and reduce periodontal pocket depth.
24% EDTA Root Conditioning
Application of 24% neutral pH EDTA gel for 3 minutes on root surfaces to remove the smear layer and expose collagen fibers before closure.
Test - OFD + EDTA + i-PRF
Participants received open flap debridement (OFD) with 24% EDTA root surface conditioning plus application of injectable platelet-rich fibrin (i-PRF) to the surgical sites before flap closure.
Open Flap Debridement (OFD)
Standard periodontal surgical procedure involving full-thickness flap elevation, scaling, and root planing to eliminate inflamed tissue and reduce periodontal pocket depth.
24% EDTA Root Conditioning
Application of 24% neutral pH EDTA gel for 3 minutes on root surfaces to remove the smear layer and expose collagen fibers before closure.
Injectable Platelet-Rich Fibrin (i-PRF)
Autologous platelet concentrate prepared by low-speed centrifugation of venous blood (\~700 rpm, 3 minutes). The upper plasma fraction rich in platelets and leukocytes was aspirated and applied to defect surfaces for approximately 5 minutes before flap closure.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Open Flap Debridement (OFD)
Standard periodontal surgical procedure involving full-thickness flap elevation, scaling, and root planing to eliminate inflamed tissue and reduce periodontal pocket depth.
24% EDTA Root Conditioning
Application of 24% neutral pH EDTA gel for 3 minutes on root surfaces to remove the smear layer and expose collagen fibers before closure.
Injectable Platelet-Rich Fibrin (i-PRF)
Autologous platelet concentrate prepared by low-speed centrifugation of venous blood (\~700 rpm, 3 minutes). The upper plasma fraction rich in platelets and leukocytes was aspirated and applied to defect surfaces for approximately 5 minutes before flap closure.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Stage II-IV periodontitis
* Presence of ≥3 adjacent teeth with probing pocket depth (PPD) ≥5 mm
* Systemically healthy individuals
* Non-smokers
* Ability and willingness to comply with oral hygiene instructions and study follow-up visits
Exclusion Criteria
* Pregnancy or lactation
* Current or previous smokers
* Use of medications that may affect periodontal status (e.g., immunosuppressants, bisphosphonates)
* Previous periodontal treatment within the last 6 months
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Halil Ata BIÇAKÇIOGLU
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Halil Ata BIÇAKÇIOGLU
Principal Investigator, PhD, Department of Periodontology, Gazi University Faculty of Dentistry
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
HALİL A BIÇAKÇIOĞLU, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Periodontology, Faculty of Dentistry, Gazi University, Ankara, Turkey
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gazi University Faculty of Dentistry, Department of Periodontology
Ankara, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GÜDHKAEK.2022.24/2
Identifier Type: REGISTRY
Identifier Source: secondary_id
GÜDHKAEK.2022.24/2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.